Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ.
Santos-Gallego CG, et al. Among authors: pinney sp.
Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95. doi: 10.1007/s10557-018-06850-0.
Cardiovasc Drugs Ther. 2019.
PMID: 30675708